Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.9, p.626–630,2021

Journal info


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564


Aims and Scope
Editorial Info
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.9, p.626–630,2021

Title: Comparison of standard prophylactic and preemptive therapeutic low molecular weight heparin treatments in hospitalized patients with COVID-19
Author: B. Copur, S. Surme, U. Sayili, G. Tuncer, E. Zerdali, M. Yazla, I. Y. Nakir, A. Buyukyazgan, A. R. Kurt-Cinar, H. Balli, Y. Kurekci, F. Pehlivanoglu, G. Sengoz

Abstract: NTRODUCTION: Anticoagulant treatment approach in patients with COVID-19 is not well studied and not standardized. We aimed to compare the effects of standard prophylactic and pre-emptive therapeutic Low-Molecular-weight Heparin (LMWH) treatment approaches on mortality in patients with COVID-19.

PATIENTS AND METHODS: This retrospective and single-centre study includes patients aged ≥ 18 years, who were diagnosed with COVID-19 and treated with LMWH during the hospital stay. Therapeutic dose of LMWH was defined as 1 mg/kg subcutaneously twice daily and prophylactic dose of LMWH was defined as 40 mg subcutaneously once daily.
RESULTS: Among the 336 patients diagnosed with COVID-19 pneumonia, 115 patients, who received LMWH were included in the study. The mean age was 58.6 ± 13.3 and 58 (50.4 %) of the patients were male. Sixty-nine (60 %) of the patients were treated with prophylactic and 46 (40 %) therapeutic LMWH.In-hospital mortality was not different between patients treated therapeutic LMWH and prophylactic LMWH by the multivariate regression analysis (OR=2.187, 95% CI 0.484–9.880, p=0.309) and the propensity score modelling (OR=1.586, 95% CI 0.400–6.289, p=0.512.)
CONCLUSION: Clinicians should consider the potential risks and benefits of standard prophylactic and pre-emptive therapeutic LMWH. Therefore, anticoagulant therapy should be individualized in patients with COVID-19 (Tab. 3, Ref. 28).

Keywords: anticoagulant therapy, COVID-19, Low-molecular-weight heparin (LMWH), mortality, outcome
Published online: 31-Aug-2021
Year: 2021, Volume: 122, Issue: 9 Page From: 626, Page To: 630

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.